The complementary mechanisms of a basal insulin and a GLP-1 RA allow IDegLira to achieve glycemic control and manage body weight when compared to other therapy strategies for patients with uncontrolled T2D on basal insulin, such as increasing doses of basal insulin. The gene discussed is INS; the disease is type 2 diabetes mellitus.